This is part one of a two-part interview with Matthew Feshbach, CEO and Co-Founder of Okyanos (pronounced “Oh – key – AH – nos”). Founded in 2011, Okyanos is an innovative stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic conditions.
Okyanos Cell Therapy delivers a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) using internationally-approved technology to patients with chronic, degenerative conditions.
Treatments are performed in their purpose-built, state-of-theart cell therapy center, led by Dr. Jeffrey Hartog, a U.S. double board-certified plastic and cranio-maxillo facial surgeon. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. [Read more…]